Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression. Tanyi, J., Dorigo, O., Oza, A. M., Strauss, J., Pejovic, T., Ghamande, S. A., Ghatage, P., Villella, J. A., Fiset, S., MacDonald, L., Hrytsenko, O., Stanford, M., Newton, R. C., Leopold, L., Rosu, G. AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.15_suppl.5576
View details for Web of Science ID 000487345805567